SeekIn Gets CE Mark for Its SeekInClarity Cancer Treatment Response Monitoring Kit

Shenzhen, China-based SeekIn has received a CE mark for its SeekInClarity cancer treatment response monitoring kit, a blood-based assay that measures circulating tumor DNA.

The blood biomarker assay combines whole-genome sequencing and protein analysis to calculate the tumor burden, to “better evaluate the efficacy of various therapies including chemotherapy, targeted therapy, immunotherapy or combination therapy,” the company said.

SeekIn said it will now launch the test in the European Union and other countries that recognize CE mark. The company specializes in blood-based cancer early detection and monitoring technology.